Effect of Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) on Weight Loss Following Bariatric Treatment.

Kramer CK, Retnakaran M, Viana LV

The Journal of clinical endocrinology and metabolism1 Jul 2024Cited by 22 (Europe PMC)

PMID38488042DOI10.1210/clinem/dgae176PepBankPUB-38488042

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone10

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

01HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In 14 observational studies after bariatric treatment, pooled GLP-1RAs (including liraglutide) reduced body weight by 7.83 kg compared with before treatment.
In plain wordsAfter bariatric surgery, GLP-1 drugs such as liraglutide were linked to a 7.83 kg weight reduction compared with before treatment.
Peptide
Liraglutide
Outcome
DecreaseWeight change in observational studies
Study
n: not reported in source
Comparator
Pre-treatment baseline
Outcome group
Body weight · Metabolic and weight
Measurements
Weight change
−7.83 kg
14 observational studies, vs pre-treatment
Source sentences
Summary
Pooling the data from the 14 observational studies evaluating the effect of GLP-1RAs post bariatric treatment demonstrated a reduction of 7.83 kg compared to pre treatment (before the use of GLP-1RA) (weight-7.83 kg [95% CI, -9.27 to -6.38]).
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 17 studies (1164 participants) met our inclusion criteria.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3848804201
02HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In randomized trials after bariatric treatment, pooled GLP-1RAs (including liraglutide) induced a weight reduction of 4.36 kg compared with placebo.
In plain wordsAfter bariatric surgery, GLP-1 drugs such as liraglutide led to 4.36 kg more weight reduction than placebo in trials.
Peptide
Liraglutide
Outcome
DecreaseWeight change in randomized trials
Study
n: not reported in source
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Measurements
Weight reduction
−4.36 kg
RCTs, vs placebo
Source sentences
Summary
Data from RCTs showed that the use of GLP-1RAs induced weight reduction of 4.36 kg (95% CI, -0.42 to -8.30) compared to placebo with a similar safety profile.
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 17 studies (1164 participants) met our inclusion criteria.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3848804202
03HumanNot a test of Liraglutide aloneSystematic reviewSafety outcome
After bariatric treatment, 23% of participants on pooled GLP-1RAs (including liraglutide) reported any adverse event.
In plain wordsAfter bariatric surgery, 23% of people on GLP-1 drugs such as liraglutide reported any adverse event.
Peptide
Liraglutide
Outcome
Not applicableAny adverse event
Study
n: not reported in source
Outcome group
Adverse events · Whole body
Measurements
Participants reporting any adverse event
23%
pooled
Source sentences
Summary
With respect to tolerability, 23% (95% CI, 10%-36%) of participants reported any adverse event
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 17 studies (1164 participants) met our inclusion criteria.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3848804203
04HumanNot a test of Liraglutide aloneSystematic reviewSafety outcome
After bariatric treatment, 7% of participants on pooled GLP-1RAs (including liraglutide) discontinued treatment.
In plain wordsAfter bariatric surgery, 7% of people on GLP-1 drugs such as liraglutide stopped treatment.
Peptide
Liraglutide
Outcome
Not applicableTreatment discontinuation
Study
n: not reported in source
Outcome group
Adverse events · Whole body
Measurements
Participants who discontinued treatment
7%
pooled
Source sentences
Summary
but only 7% discontinued treatment.
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 17 studies (1164 participants) met our inclusion criteria.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3848804204
05HumanNot a test of Liraglutide aloneSystematic reviewSafety outcome
In randomized trials after bariatric treatment, pooled GLP-1RAs (including liraglutide) had a similar safety profile to placebo.
In plain wordsAfter bariatric surgery, GLP-1 drugs such as liraglutide had a similar safety profile to placebo in trials.
Peptide
Liraglutide
Outcome
No significant changeSafety profile versus placebo in RCTs
Study
n: not reported in source
Comparator
Placebo
Outcome group
Adverse events · Whole body
Source sentences
Summary
with a similar safety profile.
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 17 studies (1164 participants) met our inclusion criteria.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3848804205
06HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome
In patients after metabolic bariatric surgery, pooled GLP-1 receptor agonists reduced weight by 7.83 kg from pre-treatment in 14 observational studies.
In plain wordsIn people after weight-loss surgery, pooled GLP-1 drugs were linked to a 7.83 kg weight drop from before treatment.
Peptide
Semaglutide
Outcome
DecreaseWeight change after bariatric surgery (observational studies)
Study
n: not reported in source
Comparator
Pre-treatment baseline
Outcome group
Body weight · Metabolic and weight
Measurements
Weight change
−7.83 kg
14 observational studies
Source sentences
Summary
Pooling the data from the 14 observational studies evaluating the effect of GLP-1RAs post bariatric treatment demonstrated a reduction of 7.83 kg compared to pre treatment (before the use of GLP-1RA) (weight-7.83 kg [95% CI, -9.27 to -6.38]).
2 context sentences(design, population, supporting numbers)
Summary · context
We conducted a systematic review and meta-analysis to evaluate the effect of GLP-1RAs on weight changes in patients who previously underwent MBS.
Summary · context
A total of 17 studies (1164 participants) met our inclusion criteria.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3848804206
07HumanNot a test of Semaglutide aloneSystematic reviewSafety outcome
In patients after metabolic bariatric surgery, 23% reported any adverse event with pooled GLP-1 receptor agonists.
In plain wordsIn people after weight-loss surgery, 23% had any side effect while taking GLP-1 drugs as a pooled group.
Peptide
Semaglutide
Outcome
Not applicableAny adverse event
Study
n: not reported in source
Outcome group
Adverse events · Whole body
Measurements
Any adverse event
23%
pooled GLP-1RAs
Source sentences
Summary
With respect to tolerability, 23% (95% CI, 10%-36%) of participants reported any adverse event but only 7% discontinued treatment.
2 context sentences(design, population, supporting numbers)
Summary · context
We conducted a systematic review and meta-analysis to evaluate the effect of GLP-1RAs on weight changes in patients who previously underwent MBS.
Summary · context
A total of 17 studies (1164 participants) met our inclusion criteria.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3848804207
08HumanNot a test of Semaglutide aloneSystematic reviewSafety outcome
In patients after metabolic bariatric surgery, 7% discontinued pooled GLP-1 receptor agonist treatment.
In plain wordsIn people after weight-loss surgery, 7% stopped taking GLP-1 drugs as a pooled group.
Peptide
Semaglutide
Outcome
Not applicableTreatment discontinuation
Study
n: not reported in source
Outcome group
Adverse events · Whole body
Measurements
Discontinuation
7%
pooled GLP-1RAs
Source sentences
Summary
With respect to tolerability, 23% (95% CI, 10%-36%) of participants reported any adverse event but only 7% discontinued treatment.
2 context sentences(design, population, supporting numbers)
Summary · context
We conducted a systematic review and meta-analysis to evaluate the effect of GLP-1RAs on weight changes in patients who previously underwent MBS.
Summary · context
A total of 17 studies (1164 participants) met our inclusion criteria.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3848804208
09HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome
In patients after metabolic bariatric surgery, pooled GLP-1 receptor agonists reduced weight by 4.36 kg versus placebo in randomised trials.
In plain wordsIn people after weight-loss surgery, pooled GLP-1 drugs cut weight by 4.36 kg more than placebo in randomised trials.
Peptide
Semaglutide
Outcome
DecreaseWeight change after bariatric surgery (RCTs)
Study
n: not reported in source
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Measurements
Weight change
−4.36 kg
RCTs vs placebo
Source sentences
Summary
Data from RCTs showed that the use of GLP-1RAs induced weight reduction of 4.36 kg (95% CI, -0.42 to -8.30) compared to placebo with a similar safety profile.
2 context sentences(design, population, supporting numbers)
Summary · context
We conducted a systematic review and meta-analysis to evaluate the effect of GLP-1RAs on weight changes in patients who previously underwent MBS.
Summary · context
A total of 17 studies (1164 participants) met our inclusion criteria.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3848804209
10HumanNot a test of Semaglutide aloneSystematic reviewSafety outcome
In patients after metabolic bariatric surgery, pooled GLP-1 receptor agonists had a safety profile similar to placebo in randomised trials.
In plain wordsIn people after weight-loss surgery, pooled GLP-1 drugs had a similar safety profile to placebo in randomised trials.
Peptide
Semaglutide
Outcome
No significant changeSafety profile in RCTs
Study
n: not reported in source
Comparator
Placebo
Outcome group
Adverse events · Whole body
Source sentences
Summary
with a similar safety profile.
2 context sentences(design, population, supporting numbers)
Summary · context
We conducted a systematic review and meta-analysis to evaluate the effect of GLP-1RAs on weight changes in patients who previously underwent MBS.
Summary · context
A total of 17 studies (1164 participants) met our inclusion criteria.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3848804210

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Versions 3 to 38Current
28 Oct 2026, 02:04 UTC
The same notice was added 36 times, first on 9 Oct 2026, 18:17 UTC. The status did not change between them.
Study results updated
Version 2
9 Oct 2026, 03:06 UTC
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Effect of Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) on Weight Loss Following Bariatric Treatment.

Summary

Results from this study10

Studies that did not test the peptide alone10

Version history

Subjects

Publication types

MeSH terms

Keywords